Benzinga's Top Pre-Market NASDAQ Losers (SGEN, ARNA, HGSI, GOLD)

Seattle Genetics Inc SGEN dipped 4.87% to $12.10 in the pre-market session. SGEN's leukemia drug, Lintuzumab for acute meyeloid leukemia (AML) patients, has failed its trial. Arena Pharmaceuticals Inc ARNA lost 0.71% to $6.96 in the pre-market session. ARNA's trailing-twelve-month operating margin tumbled 1,051.95%. Human Genome Sciences Inc HGSI fell 0.47% to $29.85 in the pre-market session. HGSI's trailing-twelve-month operating margin fell 85.07%. Randgold Resources Ltd GOLD slipped 0.20% to $93.69 in the pre-market trading. GOLD's quarterly revenue fell 0.80% y/y. Read more from Benzinga's Company news.